key: cord-0998911-d3rytiw5
authors: Pyrć, Krzysztof; Milewska, Aleksandra; Duran, Emilia Barreto; Botwina, Paweł; Lopes, Rui; Arenas-Pinto, Alejandro; Badr, Moutaz; Mellor, Ryan; Kalber, Tammy L.; Fernandes-Reyes, Delmiro; Schätzlein, Andreas G.; Uchegbu, Ijeoma F.
title: SARS-CoV-2 inhibition in human airway epithelial cells using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray
date: 2020-12-10
journal: bioRxiv
DOI: 10.1101/2020.12.10.413609
sha: 2a8f355f815e5adf7d062232f65e9eec7a0a48bf
doc_id: 998911
cord_uid: d3rytiw5

There are currently no cures for coronavirus infections, making the prevention of infections the only course open at the present time. The COVID-19 pandemic has been difficult to prevent, as the infection is spread by respiratory droplets and thus effective, scalable and safe preventive interventions are urgently needed. We hypothesise that preventing viral entry into mammalian nasal epithelial cells may be one way to limit the spread of COVID-19. Here we show that N-palmitoyl-N-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycolchitosan (GCPQ), a positively charged polymer that has been through an extensive Good Laboratory Practice toxicology screen, is able to reduce the infectivity of SARS-COV-2 in A549ACE2+ and Vero E6 cells with a log removal value of −3 to −4 at a concentration of 10 – 100 μg/ mL (p < 0.05 compared to untreated controls) and to limit infectivity in human airway epithelial cells at a concentration of 500 μg/ mL (p < 0.05 compared to untreated controls). GCPQ is currently being developed as a pharmaceutical excipient in nasal and ocular formulations. GCPQ’s electrostatic binding to the virus, preventing viral entry into the host cells, is the most likely mechanism of viral inhibition. Radiolabelled GCPQ studies in mice show that at a dose of 10 mg/ kg, GCPQ has a long residence time in mouse nares, with 13.1% of the injected dose identified from SPECT/CT in the nares, 24 hours after nasal dosing. With a no observed adverse effect level of 18 mg/ kg in rats, following a 28-day repeat dose study, clinical testing of this polymer, as a COVID-19 prophylactic is warranted.

There are currently no cures for a wide variety of viral infections, including the ones caused by emerging flaviviruses and coronaviruses, which are regularly causing local outbreaks, epidemics, and pandemics 1 . Respiratory infections seem to be of special importance, as due to the transmission route, it is almost impossible to control the spread in the population. While common respiratory infections are frequently neglected, it should be borne in mind that seasonal influenza virus claims 200,000 -500,000 lives annually 2 . The year 2020 brought us the third zoonotic coronavirus in the 21 st century -SARS-CoV-2, causing the COVID-19 disease 1 . COVID-19 ranges from mild, self-limiting respiratory tract illness to severe progressive viral pneumonia, multiorgan failure and death 1 . By the beginning of the year the race to develop drugs or re-purpose drugs to prevent coronaviral infection or ease the symptoms had started. Unfortunately, most of the efforts were futile, and the most promising agents such as remdesivir 3 and convalescent plasma 4 did not live up to their expectations. While passive and active immunisation efforts are ongoing, there is still a need for novel prophylaxis interventions, especially as some of the more promising vaccine technologies neutralise systemic virus, but not viral particles within the nasal epithelia, making it impossible to tell if vaccinated persons would not still transmit the disease 5 . Here, we describe the activity of a polymer that has been developed previously as a pharmaceutical excipient, has been through a Good Laboratory Practice (GLP) toxicology screen [6] [7] [8] [9] and may readily be used to prevent or limit COVID-19 infections, e.g., in health-care workers or other persons at risk from severe disease.

Viral binding to cell-surface receptors present in the respiratory tract is a critical step, that enables SARS-CoV-2 to enter the cell and initiate replication. SARS-CoV-2 utilizes the receptor binding domain (RBD) on the spike (S) protein to bind to the angiotensin converting enzyme 2 (ACE2) receptor 10-12 present, amongst others, on the ciliated cells of the human respiratory epithelium 13, 14 . This enables activation of the S protein by the cell surface serine proteases and subsequent conformational change, which results in membrane fusion of the viral particle with the cell and ultimately RNA delivery to the replication site 10, 12, 15, 16 . Blockade of these early steps is a known strategy to prevent the infection of mammalian cells, and has been proven effective for e.g., neutralizing antibodies 17 and fusion inhibitors 18 .

Polymers, such as sulphated glycopolymers have been shown to inhibit the viral binding of human papilloma virus to cell surface receptors 19 . Sulphated chitosan compounds (i.e. Ncarboxymethylchitosan-N,O-sulfate) have been found to inhibit the synthesis of virus-specific proteins and the replication of HIV-1 in cultured T-cells as well as the replication of the Rausher murine leukemia virus in cultured mouse fibroblasts 20 . Additionally 6-deoxy-6bromo-N-phthaloyl chitosan 21 and chitosan itself [22] [23] [24] [25] [26] have been reported to have antiviral activity via a variety of mechanisms. It is well known that quaternary ammonium compounds (QACs) are viricidal due to mechanisms involving virion degradation and nucleic acid binding 27 . However WO2013/172725 28 reports that N-(2-hydroxypropyl)-3-trimethylammonium chitosan chloride (HTCC, Figure 1 ), a chitosan QAC with a molecular weight of 50 -190 kDa (based on viscosity) 29, 30 , and a level of quaternary ammonium groups ranging from 57% to 77% 31 , inhibits coronavirus infections (e.g. HCoV-NL63) in vitro by a mechanism that involves an inhibition of viral entry into the cell 31 . Positively charged HTCC was shown to electrostatically bind the coronaviral S proteins, blocking its interaction with the entry receptor and consequently the virus replication [30] [31] [32] . Such activity was shown for several members of the Coronaviridae family and HTCC also inhibited entry of highly pathogenic SARS-CoV-2 and MERS-CoV into cells 33 . The HTCC variant effective for the SARS-CoV-2 has a relatively high molecular weight (50 -190 kDa) 29,30 , a high level of quaternary ammonium group substitution (57 -77mole%) 33 and has not been through a GLP toxicology screen.

Here we show that a different quaternary ammonium chitosan (N-palmitoyl-N-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycolchitosan -GCPQ 6 , Figure 1 ), with a 6-O-glycol group (lacking in HTCC), a hydrophobic acyl group (lacking in both HTCC and HM-HTCC; the latter derivatised with N-dodecyl groups), a lower molecular weight (10 -30 kDa) than HTCC, a trimethyl quaternary ammonium group directly in place of the C2 amine group in chitosan, unlike HTCC (which has the hydroxypropyltrimethylammonium group attached to the C2 nitrogen), and a lower level of quaternary ammonium substitution than HTCC (less than 40 mole%) is also able to inhibit viral entry into cells. Oligochitosans without the quaternary ammonium group were inactive in inhibiting coronavirus entry into cells 30 . However the quaternary ammonium group on HTCC is not the only structural requirement for activity, as many quaternary ammonium polymers were found to be inactive in inhibiting coronavirus entry into cells 30 . Furthermore HTCC was inactive in inhibiting a number of other viruses (e.g. human herpes virus 1, influenza A, adenoviruses and enteroviruses) 30 . Molecular weight determinants of activity are also unclear, as while high molecular weight HTCCs (50 -190 kDa) 29, 30 were active against coronaviruses, chitosans of molecular weight 5 -17 kDa were more effective antiviral agents against tobacco mosaic virus in Xanthi-nk tobacco leaves (viral inhibition of 58 -87%) than chitosans with a molecular weight of 130 kDa and above 25 . It is thus clear that it is not straightforward to define the polymer structure features that will inhibit coronaviruses in cells, or indeed inhibit a broad spectrum of viruses.

We decided to study GCPQ's anti-viral properties, as crucially, GCPQ is being developed as a pharmaceutical excipient and has been through a Good Laboratory Practice (GLP) toxicology 

Vero E6 (Cercopithecus aethiops; kidney epithelial; ATCC: CRL-1586) and A549 cells with ACE2 overexpression (A549 ACE2+ ) 33 were used in the study. For all cultures Dulbecco's MEM (ThermoFisher Scientific, Poland) supplemented with 3% foetal bovine serum (heatinactivated; ThermoFisher Scientific, Poland) and antibiotics: penicillin (100 U/ml), streptomycin (100 μg/ mL), and ciprofloxacin (5 μg/ml) were used. Commercially available MucilAir HAE cultures were used for the ex vivo analysis (Epithelix Sarl, Switzerland). All cultures were carried out at 37°C under 5% CO2.

SARS-CoV2 was isolate 026V-03883 (Charité -Universitätsmedizin Berlin, Germany, European Virus Archive -Global -EVAG, https://www.european-virus-archive.com).

The XTT cell viability kit (Biological Industries, Israel) was used for the cell viability assays.

The following reagents were also used: viral DNA/RNA isolation kit (A&A Biotechnology, Poland), High-capacity cDNA reverse transcription kit (Thermo Fisher Scientific, Poland), Real-time qPCR kit (RT-HS-PCR mix probe, A&A Biotechnology, Poland) and the real-time qPCR oligonucleotides are listed in Table 1 . 

The GPCQ compounds are listed in Table 2 . The compounds were suspended in 1 × PBS to the final concentration of 5 mg/ mL. All stocks were stored at 4°C until use. 

The cytotoxicity of compounds was assessed by incubating confluent monolayers of Vero E6 and A549 ACE2+ cells with a range of GCPQ compound concentrations. The XTT assay was Table 1 .

The reaction was carried out using the 7500 Fast Real-Time PCR machine (Life Technologies, Poland) according to the scheme: 2 min at 50°C and 10 min at 92°C, followed by 40 cycles of 15 s at 92°C and 1 min at 60°C. In order to assess the copy number for N gene, DNA standards were prepared, as described before 36 

Four GCPQ polymers (see Table 2 ) were tested. First, the cytotoxicity of polymers was analysed on Vero E6 and A549 ACE2+ cells. The results of the analysis are shown in Figure 2 . Table 2. For the virus assays, only non-toxic concentrations were tested: 10 μg/ml of GCPQa, 25 μg/ml for GCPQc, and 200 μg/ml for GCPQb and GCPQd.

The anti-viral activity of GPCQs was analysed on Vero E6 and A549 ACE2+ cells. Each analysis was performed in triplicate, and the experiment was repeated twice. The results are presented in Figure 3 . The assay showed inhibition of SARS-CoV2 replication in the presence of GCPQa and GCPQc at non-toxic concentrations. Our analysis demonstrated that GCPQa and GCPQc effectively inhibit SARS-CoV-2 replication in vitro at non-toxic concentrations. GCPQa showed the highest toxicity, but at the same time highest anti-SARS-CoV-2 potential (~4 logs decrease in viral load at 10 μg/mL).

The effectiveness of GCPQ in the artificial cell culture systems has its drawbacks and for that reason it is of importance to validate the observations in more complex systems that replicate the host-pathogen interactions. For example, we have observed lack of toxicity in vivo at much 

The intranasal delivery of GCPQ to mouse nares resulted in the polymer being detectable within the nares area of the mouse head up to 24 hours after dosing as would be expected since the polymer is mucoadhesive 9 . 3D ROI's of the GCPQ uptake on SPECT images indicated that directly after administration (30 min) 28.22% of the administered dose was found to be within the nares, after 2h 30 min this had reduced slightly to 25.13% of the administered dose and at 24 h, 13.13% of the administered dose was found to be retained in the nares. Ex vivo curimeter analysis of the mouse head at 24 h, also confirmed that 13.5% of the administered dose was still present in the mouse head, which is slightly higher than that obtained by SPECT, but is reflective of the radioactivity within the whole head and not just the nares area. 

Here we introduce GCPQ, a low molecular weight chitosan derivative with features that unexpectedly confer anti-viral activity. GPCQ is being developed as a pharmaceutical excipient, has been through a GLP toxicology screen and a no observed adverse effect level (NOAEL) determined for a 28 day repeat dose in the rat (18 mg/ kg) 7 . It is the key excipient in the enkephalin pain therapeutic being developed by NCATS. Human nasal concentrations in excess of 1mg/ mL will be obtained by dosing 1mg in each nare, a dose of 0.03 mg/ kg that is 600 fold lower than the NOAEL dose. A low molecular weight clearly promotes activity against SARS-COV-2 in mammalian cells (Table 2 and Figures 3 -4) and this is correlated with the ease with which this polymer may be incorporated into aqueous media. Glycol chitosans of molecular weights 40 kDa and 100 kDa were not active (data not shown), demonstrating that quaternary ammonium and possibly palmitoyl groups are important determinants of activity. We speculate that GCPQ acts by binding to the virus via electrostatic interactions in a similar manner to HTCC [30] [31] [32] .

GCPQ possesses some advantages for use in viral inhibition and specifically the clinical prevention of viral infections as GCPQ is mucoadhesive 9 , has a long residence time in the nares ( Figure 5 ) and is chemically stable for at least 18 months 6 . GCPQ also self assembles into nanoparticles and these nanoparticles may be clustered into microparticles for nasal delivery 7 , as required by the regulator 37 . We hypothesise that GCPQ could be used as a molecular mask nasal spray for the prevention of coronavirus infections. The new data showing that SARS-COV-2's neurological symptoms (such as loss of smell and taste, headache, fatigue, nausea and vomiting in more than one-third of individuals and impaired consciousness) is correlated with the entry of SARS-COV-2 into the brain via the olfactory neurons, due to presence of the virus in the nasal cavity 38 , means that local interventions, such as with GCPQ that limit viral cell entry in the nasal cavity could have a profound impact on the course and severity of the disease.

The potential applicability of GCPQ in the prevention of viral infections is supported by the fact that carrageenans (anionic sulphated carbohydrates) have been shown to reduce the duration of disease (reduced by 3 days) in influenza and common cold patients (reduced the number of relapses over a 21 day period by three times) and prevent influenza A viral infections in mice, acting by preventing viral interaction with relevant cell surface receptors 39, 40 .

As GCPQ's activity is not predicated specifically on the recognition of particular epitopes but appears to be based on electrostatic interactions between GCPQ and the virus, it is possible that GCPQ may be applied to a wide variety of viral infections. These advantages mean that GCPQ may be given as a nasal spray or by other means for the prevention and treatment of specific viral infections.

A mucoadhesive polymer with anti-SARS-COV-2 activity is presented. The polymer may be used as a nasal spray to prevent SARS-COV-2 infections.

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR Project

Covid-19: Remdesivir has little or no impact on survival, WHO trial shows

Convalescent plasma is ineffective for covid-19

A SARS-CoV-2 mRNA Vaccine -Preliminary Report

Physical characterisation and long-term stability studies on quaternary ammonium palmitoyl glycol chitosan (GCPQ)--a new drug delivery polymer

Nanoparticulate peptide delivery exclusively to the brain produces tolerance free analgesia

Oral particle uptake and organ targeting drives the activity of amphotericin B nanoparticles

Enhanced oral absorption of hydrophobic and hydrophilic drugs using quaternary ammonium palmitoyl glycol chitosan nanoparticles

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

Replication of Severe Acute Respiratory Syndrome Coronavirus 2 in Human Respiratory Epithelium

Kallikrein 13 serves as a priming protease during infection by the human coronavirus HKU1

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. bioRxiv

Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Prophylactic Antiviral Activity of Sulfated Glycomimetic Oligomers and Polymers

The improved antiviral activities of amino-modified chitosan derivatives on Newcastle virus

Intranasal Administration of Chitosan Against Influenza A (H7N9) Virus Infection in a Mouse Model

Antioxidant, antifungal and antiviral activities of chitosan from the larvae of housefly, Musca domestica L

Effect of Chitosan on the Infectivity of Murine Norovirus, Feline Calicivirus, and Bacteriophage MS2

Cell death-mediated antiviral effect of chitosan in tobacco

Quaternary ammonium biocides: efficacy in application

The use of chitosan polymer in the treatment and prevention of infections caused by coronaviruses

Chitosan -Low Molecular Weight

Novel polymeric inhibitors of HCoV-NL63

HTCC: Broad Range Inhibitor of Coronavirus Entry

Biopolymeric nano/microspheres for selective and reversible adsorption of coronaviruses

HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoV

Polymeric micellar clusters and their use in formulating drugs

A prodrug nanoparticle approach for the oral delivery of a hydrophilic peptide, leucine(5)-enkephalin, to the brain

Replication of Severe Acute Respiratory Syndrome Coronavirus 2 in Human Respiratory Epithelium

Committee for Medicinal Products for Human Use -Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products

Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19

Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials

Iota-carrageenan is a potent inhibitor of influenza A virus infection

IFU and AGS are directors of Nanomerics Ltd.

IFU and AGS conceived of the study and IFU drafted the manuscript. KP, AM, EBD and PB carried out the in vitro tests and KP contributed to the writing of the manuscript. RL and TLK carried out the animal studies. MB synthesised the GCPQ, RM synthesised glycol chitosan and provided information on GCPQ, AAP and DFR contributed to the discussion in the manuscript.